Table 1. Patients' characteristics.

patient	sex	age (y)	disease	stage	previous Tx	site of Bx	Bx to PET	PentixaforPET/CT	DOTATOCPET/CT	FDGPET/CT	CXCR4IRS	SSTR2IRS	SSTR5IRS
1	m	69	SCLC	ED	RCTx	primary	2 months	+	+	n/a	8	0	0
2	f	38	SCLC	ED	none	metastasis	1 week	−	n/a	+	10	0	4
3	m	63	SCLC	ED	RCTx	metastasis	3 weeks	+	-	n/a	4	0	4
4	f	62	SCLC	ED	CTx	primary	4 weeks	+	n/a	+	4	0	0
5	f	49	SCLC	LD	none	primary	2 weeks	+	n/a	+	0	0	0
6	f	74	LCNEC	ED	RCTx	metastasis	5 months	−	−	+	12	0	0
7	m	63	SCLC	ED	RCTx	metastasis	2 weeks	+	−	n/a	4	4	4
8	m	56	SCLC	ED	RCTx	primary	8 months	+	n/a	+	8	0	0
9	m	79	SCLC	ED	CTx	primary	2 months	+	+	n/a	3	4	0
10	f	67	SCLC	LD	none	primary	2 weeks	+	n/a	+	4	4	0

All patients with relapsed disease had undergone 1^st- and/or 2^nd-line treatment (patients #1, #3, #9). 1^st-line treatment included 2-6 cycles of platinum/etoposide-containing chemotherapy (patient #1: 2 cycles, patients #3 and #9: 4 cycles, patients #4, #6, #7 and #8: 6 cycles) (+radiotherapy), 2^nd-line therapy had topotecan as the mainstay (all three patients [#1, #3 and #9] received 6 cycles).

Bx = biopsy; CTx = chemotherapy; IRS = immunoreactive score; LCNEC = large cell neuroendocrine carcinoma of the lung; LN = lymph node; N/A = not assessed; PD= primary diagnosis; RCTx = radio-chemotherapy; SCLC= small cell lung cancer; Tx = treatment.